Trial Profile
AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2014
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ACE-CTO
- 31 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 31 Mar 2014 Optical coherence tomography outcome results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.